-
Percutaneous coronary intervention (PCI) is performed in more than 600,000 patients annually in the United States, and women make up approximately one-third of this population.
-
This paper reviews drug therapy in patients with atrial fibrillation in the Medicare population. The author extracted a 5% sample of Medicare beneficiaries who were enrolled in Medicare Part D.
-
-
This paper details the result of a population-based cohort study of all Ontario, Canada, residents older than 66 years of age who began warfarin therapy for atrial fibrillation over an 11-year period.
-
Angioedema is an infrequent, but serious, adverse event from drug therapy. Drugs that affect the renin-angiotensin-aldosterone system have been linked to angioedema, but the relative frequency of this complication with these drugs is poorly understood.
-
As our population ages and outcomes from revascularization also improve, more elderly patients are being referred for coronary artery bypass graft surgery (CABG) and for percutaneous coronary intervention (PCI).
-
Zolpidem and risk of falls; AVR and anticoagulation; statins in cancer patients; and FDA actions.
-
This study, the Multicenter Automatic Defibrillator Implantation Trial Reduce Inappropriate Therapy (MADIT-RIT), was designed to test the hypothesis that programming implantable cardioverter-defibrillator (ICD) therapies with higher detection rates or delayed detection before initiation of therapy would decrease inappropriate shocks in ICD patients.
-
-